Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126208 | 0.93 | CCR2 (0.47) | CCR2 | |
| SCHEMBL5124876 | 0.88 | SIGMAR1 (0.57) | — | |
| SCHEMBL5130455 | 0.86 | BCHE (0.49) | KMT2ADRD4BCHELMNASMN1; SMN2 | |
| SCHEMBL5117306 | 0.86 | CCR8 (0.47) | SMN1; SMN2 | |
| SCHEMBL5118332 | 0.85 | CCR8 (0.47) | SMN1; SMN2 | |
| SCHEMBL5165517 | 0.84 | CCR8 (0.46) | SMN1; SMN2 | |
| SCHEMBL5127760 | 0.84 | SIGMAR1 (0.51) | KMT2ADRD4ACHEBCHECACNA1F | |
| SCHEMBL5121666 | 0.82 | CYP2C19 (0.53) | SMN1; SMN2 | |
| SCHEMBL5119081 | 0.81 | CCR8 (0.45) | SMN1; SMN2 | |
| SCHEMBL4840680 | 0.79 | CCR2 (0.76) | CCR2KMT2ADRD4ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | claimed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| EP-1768955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | CCR2 3457/4885KMT2A 223/4885DRD4 4839/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | CCR2 3457/4885KMT2A 223/4885DRD4 4839/4885 |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC4 | CCR2 2681/4885KMT2A 44/4885DRD4 3197/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | CCR2 3457/4885KMT2A 223/4885DRD4 4839/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | CCR2 3541/4885KMT2A 215/4885DRD4 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.